Information Provided By:
Fly News Breaks for May 19, 2016
MRK, BMY
May 19, 2016 | 08:53 EDT
After reviewing ASCO data, BMO Capital believes that Bristol Myers' (BMY) Opdivo drug, in combination with Yervoy will be at best used in a limited number of 1L NSCLC patients. The firm believes that the combination of Opdivo and Merck's (MRK) Keytruda is poised to become the new standard of care for the disease. BMO says that this development is negative for Bristol-Myers.
News For BMY;MRK From the Last 2 Days
MRK
Mar 28, 2024 | 06:48 EDT
Merck announced that the European Commission has approved Keytruda, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
MRK
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 08:55 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Robinhood (HOOD)... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 07:19 EDT
BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including "a lot of investor angst" given the risk for the FDA to issue either black box warnings, REMS, and/or monitoring requirement. However, sotatercept's approval in PAH with the brand name Winrevair "comes with a squeaky-clean label," without WHO functional class restriction or a need to be on background therapy, no black box and no REMS, which represents "the most bullish scenario," the analyst tells investors. The firm, which anticipates Merck shares to react favorably, maintains a Buy rating and $135 price target and sees upside to sotatercept's commercial outlook.
MRK
Mar 27, 2024 | 06:12 EDT
Wells Fargo raised the firm's price target on Merck to $135 from $130 and keeps an Equal Weight rating on the shares. The firm notes WINREVAIR, or sotatercept, was approved with simple monitoring on the label, removing an overhang on the stock. $242k annual pricing is competitive and could enable the drug to move into earlier lines, and Wells now models $7B peak sales opportunity.